ArticleDiabetic medicine : a journal of the British Diabetic Association2026
The insulin-like growth factor system and the progression of renal complications of type 2 diabetes.
Article in Diabetic medicine : a journal of the British Diabetic Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsChronic kidney disease is associated with dysregulation of the insulin-like growth factor (IGF) system. Alterations in IGF bioavailability, driven by IGF binding proteins (IGFBPs), may influence the decline in renal function. However, the longitudinal relationship between baseline IGF-I, IGF-II, IGFBPs and progression of kidney dysfunction remains unclear. We evaluated how IGF/IGFBP profile relates to longitudinal changes in urinary albumin/creatinine ratio (ACR) and serum creatinine level in people with type 2 diabetes (T2D).
methodsIndividuals' measurements were performed in 436 individuals with T2D recruited from primary and secondary care (2002-2004), from the Salford and Manchester Integrated Care Record (GMCR), for laboratory and clinical data, as well as date of death. Baseline IGF/IGFBP profile was related to 2 primary outcomes: (i) change in albumin-to-creatinine ratio over time (urine ACR trend slope) and (ii) change in serum creatinine over time (creatinine trend slope). Trend slopes were derived for each participant, using repeated measures throughout follow-up for up to 24 years. Associations between IGF axis proteins and outcomes were evaluated with multivariate regression models. Cox proportional hazards models were constructed to determine mortality risk associated with the IGF system proteins studied.
resultsAt baseline, 59.3% of participants were men. Age at baseline was 56.6 ± 9.4 years. Mean follow-up duration was 17.4 ± 5.2 years. IGF-II and IGFBP-3 were strongly correlated (Spearman rho = 0.80), and were therefore not included simultaneously in the multi-variate linear regression model to avoid co-linearity. Higher circulating IGFBP-2 was independently associated with faster rate of ACR progression (normalised beta (Β) = 0.007, p = 0.002), while IGFBP-1 showed an inverse association (B = -0.057, p = 0.009). IGF-II also remained positively associated with ACR trend (B = 0.005, p = 0.013), whereas IGF-I showed no association. IGFBP-1 showed a significant inverse association with creatinine change when adjusted for effects of covariates (unstandardised B = -0.038, p = 0.04). Survival analysis revealed that higher IGFBP-2 levels were independently associated with higher all-cause mortality (hazard ratio [HR] per 1 standard deviation increase 1.306, 95% CI 1.151-1.483 p = 0.0001).
conclusionThis longitudinal study indicated that higher baseline IGF-II, lower IGFBP-1 and higher IGFBP-2 are associated with a greater likelihood of albuminuria progression, independent of standard risk factors; lower IGBFP-1 also associated with greater increase in serum creatinine. Higher circulating IGFBP-2 level was also associated with relatively higher mortality. This study demonstrated the relevance of the IGF system to our understanding of renal complications in diabetes and strongly suggests that further exploration of mechanisms underlying these associations is merited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.